title: Does HIV infection alter the incidence or pathology of Helicobacter pylori infection?
abstract: Gastrointestinal (GI) discomfort is a common complaint among patients infected with HIV. GI symptoms can be caused by a myriad of factors including but not limited to coinfections, antiretroviral therapy, medications for opportunistic infections, and nutritional status. Some researchers have hypothesized that Helicobacter pylori infection may be more common among HIV-infected patients as a result of immune suppression. An increased incidence of H. pylori infection would contribute to the prevalence of GI complaints in this population. Several epidemiologic studies have examined the relationship between H. pylori infection and HIV. While studies have generally reported conflicting results that may be related to the use of varied study designs, some identifiable patterns can be discerned. It does appear that the incidence of H. pylori infection is lower among patients with AIDS compared to matched HIV-infected and -uninfected controls. This review discusses the various epidemiologic trials that have been conducted in this area and describes the potential physiologic mechanisms to explain these findings. The clinical applicability of these studies as well as limitations are also discussed. A greater number of well-designed and controlled trials are needed before any definitive conclusions regarding these diseases can be made, until such time clinicians should be aware of the potential issues regarding H. pylori screening and management in the context of HIV. Research in this area might also provide information relating to HIV-associated GI changes and the role of these changes in HIV pathogenesis.
authors.affiliation: College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536, USA. froma2@uky.edu
authors.forename: Frank
authors.initials: F
authors.lastname: Romanelli
authors.forename: Kelly M
authors.initials: KM
authors.lastname: Smith
authors.forename: Brian S
authors.initials: BS
authors.lastname: Murphy
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D015331:Cohort Studies; D005756:Gastritis / Q000209:etiology / Q000382:microbiology / Q000473:pathology; D015658:HIV Infections / Q000150:complications*; D016481:Helicobacter Infections / Q000209:etiology / Q000276:immunology / Q000473:pathology; D016480:Helicobacter pylori / Q000276:immunology / Q000302:isolation & purification / Q000472:pathogenicity; D006801:Humans; D012307:Risk Factors
chemical_list: D000900:Anti-Bacterial Agents; D044966:Anti-Retroviral Agents